Published On: Wed, Sep 13th, 2017

Trinity Biotech Plc (NASDAQ:TRIB) – Latest Broker Consensus

Currently 4 brokers are covering Trinity Biotech plc (NASDAQ:TRIB), 1 rate it “Buy”, 3 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Below are the most recently updated broker updates which include ratings and price targets for Trinity Biotech plc (NASDAQ:TRIB).

10/05/2016 – Broker: Stephens Rating: equal weight downgrade

12/16/2015 – Broker: Roth Capital Rating: buy reiteration

10/23/2015 – Broker: Craig-Hallum Rating: hold New Target: 14 downgrade

09/03/2015 – Broker: Raymond James Rating: outperform New Target: 20 newcoverage

10/29/2014 – Broker: Zacks Rating: neutral New Target: 17.2 upgrade

11/19/2013 – Broker: Sidoti Rating: buy newcoverage

10/29/2013 – Broker: Jefferson Research Rating: hold downgrade

The average price target from the most recent broker reports is 17.07

The stock increased +1.29% (+0.07) during the last days session, reaching 5.48 and roughly 29202 shares were bought or sold by traders.